Skip to main content

Vaxcyte, Inc. (PCVX)

NASDAQ: PCVX · IEX Real-Time Price · USD
22.52 0.00 (0.00%)
Oct 21, 2021 4:00 PM EDT - Market open
Market Cap1.16B
Revenue (ttm)n/a
Net Income (ttm)-86.65M
Shares Out51.51M
EPS (ttm)-1.69
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume344
Open-
Previous Close22.52
Day's Range22.01 - 22.60
52-Week Range15.51 - 45.79
Betan/a
AnalystsStrong Buy
Price Target50.50 (+124.2%)
Est. Earnings DateNov 11, 2021

About PCVX

Vaxcyte, Inc., a preclinical-stage biotechnology vaccine company, develops novel vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting Porphyromonas gingivalis. The company was formerly known as SutroVax, Inc. and c...

IndustryBiotechnology
IPO DateJun 12, 2020
CEOGrant Pickering
Employees58
Stock ExchangeNASDAQ
Ticker SymbolPCVX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for Vaxcyte stock is "Strong Buy." The 12-month stock price forecast is 50.50, which is an increase of 124.25% from the latest price.

Price Target
$50.50
(124.25% upside)
Analyst Consensus: Strong Buy

News

Vaxcyte to Present at Guggenheim 2nd Annual Vaccine and Infectious Disease Conference

FOSTER CITY, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designe...

3 weeks ago - GlobeNewsWire

Vaxcyte to Present at 2021 Cantor Virtual Global Healthcare Conference

FOSTER CITY, Calif., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designe...

1 month ago - GlobeNewsWire

Vaxcyte Appoints Annie Drapeau and Teri Loxam to Its Board of Directors

FOSTER CITY, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designe...

1 month ago - GlobeNewsWire

Vaxcyte Reports Second Quarter 2021 Financial Results and Provides Business Update

FOSTER CITY, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed...

2 months ago - GlobeNewsWire

Vaxcyte to Present at the Jefferies Virtual Healthcare Conference

FOSTER CITY, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed ...

4 months ago - GlobeNewsWire

Vaxcyte Reports First Quarter 2021 Financial Results and Provides Business Update

FOSTER CITY, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed ...

5 months ago - GlobeNewsWire

Vaxcyte Announces Publication of Preclinical Data Supporting the Potential of VAX-24 for the Prevention of Invasive P...

VAX-24 is a 24-Valent Broad-Spectrum Pneumococcal Conjugate Vaccine Leveraging Vaxcyte's Technology Platform VAX-24 is a 24-Valent Broad-Spectrum Pneumococcal Conjugate Vaccine Leveraging Vaxcyte's Tech...

5 months ago - GlobeNewsWire

Vaxcyte to Present at 20th Annual Needham Virtual Healthcare Conference

FOSTER CITY, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designe...

6 months ago - GlobeNewsWire

Vaxcyte Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

FOSTER CITY, Calif., March 29, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designe...

6 months ago - GlobeNewsWire

Vaxcyte asks chairman Slaoui to resign after GSK harassment allegation

U.S. vaccine developer Vaxcyte Inc on Thursday asked board chairman Moncef Slaoui to step down, a day after GlaxoSmithKline dismissed him as an independent probe found he had sexually harassed a GSK emp...

6 months ago - Reuters

TPG Group Holdings (SBS) Advisors, Inc. Buys C3..

Fort Worth, TX, based Investment company TPG Group Holdings (SBS) Advisors, Inc. (Current Portfolio) buys C3.ai Inc, McAfee Corp, Vaxcyte Inc, Eros STX Global Corp, Thomson Reuters Corp, sells Uber Tech...

Other symbols:ABNBAIAPDESGCMCFETRI
6 months ago - GuruFocus

Vaxcyte to Report Fourth Quarter and Full Year 2020 Financial Results on March 29, 2021

FOSTER CITY, Calif., March 22, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designe...

6 months ago - GlobeNewsWire

Vaxcyte Announces Publication of Preclinical Proof-of-Concept Data Supporting Potential of VAX-A1, a Novel Conjugate ...

FOSTER CITY, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc., a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or ...

9 months ago - GlobeNewsWire

U.S. IPO Week Ahead: DoorDash And Airbnb Kick Off The Unicorn Parade In A 6 IPO Week

The unicorn IPO parade is set to begin in the week ahead, with DoorDash and Airbnb leading the way. A total of six IPOs and two SPACs are scheduled to raise $7.2 billion.

10 months ago - Seeking Alpha

Vaxcyte to Present at Evercore ISI 3rd Annual HealthCONx Conference

FOSTER CITY, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel vacc...

10 months ago - GlobeNewsWire

Vaxcyte Reports Third Quarter 2020 Financial Results and Provides Business Update

FOSTER CITY, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel vacc...

11 months ago - GlobeNewsWire

Vaxcyte to Present at Jefferies Virtual London Healthcare Conference

FOSTER CITY, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel vacc...

11 months ago - GlobeNewsWire

Vaxcyte to Present at 2020 Cantor Virtual Global Healthcare Conference

FOSTER CITY, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel v...

1 year ago - GlobeNewsWire

CORRECTION – Vaxcyte Reports Second Quarter 2020 Financial Results and Provides Business Update

FOSTER CITY, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- In a release issued earlier today under the same headline by Vaxcyte, Inc. (Nasdaq: PCVX), please note that in the first bullet under “Recent Hig...

1 year ago - GlobeNewsWire

Vaxcyte Reports Second Quarter 2020 Financial Results and Provides Business Update

FOSTER CITY, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel va...

1 year ago - GlobeNewsWire

Biotech IPOs are booming -- but it's not all about Covid-19

Health care companies and governments are racing to find a vaccine or other effective treatment for Covid-19 -- so investors have been piling into stocks like Gilead Sciences, Moderna and Novavax.

1 year ago - CNN Business

Vaxcyte Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional...

FOSTER CITY, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines design...

1 year ago - GlobeNewsWire

Vaccine maker Vaxcyte's shares soar 22% in trading debut

Shares of Vaxcyte Inc. soared 22% in their trading debut Friday, after the company's IPO priced at the top end of its price range, and was upsized to 15.6 million shares from earlier plans to sell just ...

1 year ago - Market Watch

Vaccine maker Vaxcyte upsizes IPO and prices at top end of range

Vaxcyte Inc. priced its initial public offering late Thursday at $16 a share, the top end of its price range, and upzied the deal to 15.6 million shares from earlier plans to sell just 14 million.

1 year ago - Market Watch